Myocardial Ischemia and Ventricular Tachycardia on Continuous Electrocardiographic Monitoring and Risk of Cardiovascular Outcomes After Non-ST-Segment Elevation Acute Coronary Syndrome (from the MERLIN-TIMI 36 Trial)

被引:13
|
作者
Harkness, James R. [1 ,2 ]
Morrow, David A. [1 ,3 ,4 ]
Braunwald, Eugene [1 ,3 ,4 ]
Ren, Fang [1 ,3 ,4 ]
Lopez-Sendon, J. [5 ]
Bode, Christopher [6 ]
Budaj, Andrzej [7 ]
Scirica, Benjamin M. [1 ,3 ,4 ]
机构
[1] TIMI Study Grp, Boston, MA USA
[2] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[3] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Hosp Univ La Paz, Madrid, Spain
[6] Med Univ Klin, Freiburg, Germany
[7] Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2011年 / 108卷 / 10期
关键词
SYNDROME-THROMBOLYSIS; METABOLIC EFFICIENCY; LESS ISCHEMIA; INFARCTION; RANOLAZINE; DEFIBRILLATOR; PREVALENCE; EVENTS; MARKER;
D O I
10.1016/j.amjcard.2011.06.058
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Among patients with non-ST-segment elevation acute coronary syndromes, recurrent ischemia and ventricular arrhythmias detected on continuous electrocardiographic monitoring remain common events that are associated with worse outcomes. The relative clinical significance of both events together is not well described. We determined the risk associated with ischemia (>= 1 mm ST depression lasting >= 1 minutes) and ventricular tachycardia (VT) (>= 4 beats) detected on 7-day continuous electrocardiographic monitoring in 6,355 patients with non-ST-segment elevation acute coronary syndromes from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation Acute Coronary Syndrome Thrombolysis In Myocardial Infarction (MERLIN-TIMI) 36 trial. The patients were categorized into 4 groups according to the presence or absence of VT and ischemia. Cardiovascular death, sudden cardiac death (SCD), myocardial infarction, and recurrent ischemia were assessed during a median follow-up of 348 days. A total of 60.0% patients had no VT or ischemia, 20.0% had VT alone, 14.7% had ischemia alone, and 5.3% had both. The patients with either VT or ischemia were at increased risk of cardiovascular outcomes. The combination of ischemia and VT identified a particularly high-risk population for cardiovascular death (10.1% vs 3.0%, p <0.001), SCD (7.8% vs 0.9%, p <0.001), and myocardial infarction (15.4% vs 6.2%, p <0.001) compared to patients with neither. The addition of arrhythmia and ischemia significantly improved the clinical model for predicting cardiovascular death or SCD (p <0.001). In patients with both ischemia and VT, 66.6% of SCD occurred within 90 days of the non-ST-segment elevation acute coronary syndromes. In conclusion, in >6,300 patients with non-ST-segment elevation acute coronary syndromes, the presence of myocardial ischemia or VT alone, and particularly in combination, was independently associated with poor cardiovascular outcomes and thus provides incremental improvement in early risk stratification. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;108:1373-1381)
引用
收藏
页码:1373 / 1381
页数:9
相关论文
共 50 条
  • [31] Myocardial revascularization eliminates the risk gradient defined by TIMI risk score in non-ST-segment elevation acute coronary syndromes
    Santos, JF
    Ferreira, J
    CIRCULATION, 2005, 112 (17) : U808 - U808
  • [32] Myocardial revascularisation eliminates the risk gradient defined by the TIMI Risk Score in non-ST-segment elevation acute coronary syndromes
    Santos, J. Ferreira
    Ferreira, J.
    EUROPEAN HEART JOURNAL, 2005, 26 : 432 - 432
  • [33] Effect of ranolazine on at a fibrilla on in patients with non-ST eleva on acute coronary syndromes: observations from the MERLIN-TIMI 36 trial
    Scirica, Benjamin M.
    Belardinelli, Luiz
    Chaitman, Bernard R.
    Waks, Jonathan W.
    Volo, Samuel
    Karwatowska-Prokopczuk, Ewa
    Murphy, Sabina A.
    Cheng, Mei L.
    Braunwald, Eugene
    Morrow, David A.
    EUROPACE, 2015, 17 (01): : 32 - 37
  • [34] B-type natriuretic peptide and the effect of ranolazine in patients with non-ST elevation acute coronary syndromes in the MERLIN-TIMI 36 trial
    Morrow, David A.
    Scirica, Benjamin M.
    Sabatine, Marc S.
    De Lemos, James A.
    Murphy, Sabina A.
    Jarolim, Petr
    Theroux, Pierre
    Bode, Christophe
    Braunwald, Eugene
    CIRCULATION, 2007, 116 (16) : 382 - 382
  • [35] Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial)
    Cox, David A.
    Stone, Gregg W.
    Grines, Cindy L.
    Stuckey, Thomas
    Zimetbaum, Peter J.
    Tcheng, James E.
    Turco, Mark
    Garcia, Eulogio
    Guagliumi, Giulio
    Iwaoka, Robert S.
    Mehra, Roxana
    O'Neill, William W.
    Lansky, Alexandra J.
    Griffin, John J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (03): : 331 - 337
  • [36] TIMI risk score and severity of coronary artery disease in patients with non-ST-segment elevation acute myocardial infarction.
    Juarez Prera, R.
    Bosa Ojeda, F.
    Ferrer Hita, J.
    Garcia Gonzalez, M.
    Rodriguez Gonzalez, A.
    Yanes Bowden, G.
    Sanchez-Grande Flecha, A.
    Vargas Torres, M.
    Blanco Palacios, G.
    Hernandez Garcia, C.
    Arroyo Ucar, E.
    CORONARY ARTERY DISEASE: 2011 UPDATE: FROM PREVENTION TO INTERVENTION, 2011, : 213 - 217
  • [37] Continuous ST-segment monitoring improves early risk stratification in patients with non-ST-segment elevation acute coronary syndromes
    Aguiar, C
    Ferreira, J
    Ribeiro, M
    Teles, R
    Cavaco, D
    Timoteo, A
    Seabra-Gomes, R
    EUROPEAN HEART JOURNAL, 2000, 21 : 184 - 184
  • [38] Atypical electrocardiographic patterns and invasive strategy in high-risk non-ST-segment elevation acute coronary syndrome
    Vega Candelario, Rodolfo
    Vega Jimenez, Junior
    CORSALUD, 2020, 12 (04): : 481 - 484
  • [39] Clinical Features and Outcomes of Women With Unstable Ischemic Heart Disease Observations From Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36)
    Mega, Jessica L.
    Hochman, Judith S.
    Scirica, Benjamin M.
    Murphy, Sabina A.
    Sloan, Sarah
    McCabe, Carolyn H.
    Merlini, Piera
    Morrow, David A.
    CIRCULATION, 2010, 121 (16) : 1809 - 1817
  • [40] PROGNOSTIC PERFORMANCE OF A SINGLE-MOLECULE HIGH-SENSITIVITY CARDIAC TROPONIN ASSAY AFTER NON-ST ELEVATION ACUTE CORONARY SYNDROME: ANALYSIS FROM MERLIN-TIMI 36
    O'Malley, Ryan G.
    Bonaca, Marc
    Sabatine, Marc
    Scirica, Benjamin
    Jarolim, Petr
    Conrad, Michael
    Murphy, Sabina
    Braunwald, Eugene
    Morrow, David
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E402 - E402